Skip to main content
logo
Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
28.41
-0.76 (-2.61%)
Nov 2, 2026, 4:00 PM EST - Market closed

Immunovant Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Market Capitalization
5,8685,0562,9034,6942,005641
Market Cap Growth
36.40%74.16%-38.16%134.16%212.60%-59.19%
Enterprise Value
5,0704,0612,5284,0041,574117
Last Close Price
29.1724.8417.0932.3115.515.51

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PB Ratio
8.185.934.107.605.531.37
P/TBV Ratio
8.045.934.107.605.531.37

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Debt / Equity Ratio
-0000.000.01
Net Debt / Equity Ratio
-1.08-1.06-1.01-1.03-1.03-1.05
Net Debt / EBITDA Ratio
1.411.691.632.351.803.15
Net Debt / FCF Ratio
1.932.221.902.961.994.62
Quick Ratio
6.828.6810.4213.188.7211.38
Current Ratio
7.279.0911.1613.709.3411.52
Return on Equity (ROE)
-80.10%-64.82%-62.46%-52.91%-50.69%-36.39%
Return on Assets (ROA)
-46.73%-38.43%-37.97%-31.50%-28.26%-21.02%
Return on Capital Employed (ROCE)
-77.00%-62.50%-61.90%-43.70%-57.40%-33.10%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Nov '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Earnings Yield
-9.91%-10.00%-14.26%-5.52%-10.52%-24.44%
FCF Yield
-7.01%-8.06%-12.97%-4.57%-9.40%-16.59%
Buyback Yield / Dilution
-21.12%-20.35%-9.76%-12.21%-12.21%-24.98%
SEC Filings: 10-K · 10-Q